Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited)

v3.22.2.2
Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) - USD ($)
Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Common stock No Par Value [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2020 $ 4,004 $ 43,411,487 $ (48,672,525) $ (5,257,034)
Balance, shares at Dec. 31, 2020   28,553,307      
Net loss (3,089,704) (3,089,704)
Balance at Mar. 31, 2021 $ 4,004 43,411,487 (51,762,229) (8,346,738)
Balance, shares at Mar. 31, 2021   28,553,307      
Balance at Dec. 31, 2020 $ 4,004 43,411,487 (48,672,525) (5,257,034)
Balance, shares at Dec. 31, 2020   28,553,307      
Net loss           (21,182,040)
Balance at Jun. 30, 2021 $ 144,524 100,784,376 (69,854,565) 31,074,335
Balance, shares at Jun. 30, 2021 72,992   37,355,650      
Balance at Mar. 31, 2021 $ 4,004 43,411,487 (51,762,229) (8,346,738)
Balance, shares at Mar. 31, 2021   28,553,307      
Exercise of prepaid equity forward contracts for common stock
Exercise of prepaid equity forward contracts for common stock, shares     466,716      
Net loss   (18,092,336) (18,092,336)
Reverse merger with Akers Biosciences Inc effective April 16, 2021 $ 144,524 85,748,325 $ (4,004) (43,411,487) 42,477,358
Reverse merger with Akers Biosciences Inc effective April 16, 2021, shares 72,992   8,335,627      
Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement 15,036,051 15,036,051
Balance at Jun. 30, 2021 $ 144,524 100,784,376 (69,854,565) 31,074,335
Balance, shares at Jun. 30, 2021 72,992   37,355,650      
Balance at Dec. 31, 2021 $ 144,524 $ 102,064,218 (78,561,568) 23,647,174
Balance, shares at Dec. 31, 2021 72,992   37,673,110      
Exercise of prepaid equity forward contracts for common stock  
Exercise of prepaid equity forward contracts for common stock, shares     385,135      
Stock-based compensation – stock options   $ 81,002 81,002
Stock-based compensation – restricted stock units   15,998 15,998
Net loss (4,122,034) (4,122,034)
Balance at Mar. 31, 2022 $ 144,524 $ 102,161,218 (82,683,602) 19,622,140
Balance, shares at Mar. 31, 2022 72,992   38,058,245      
Balance at Dec. 31, 2021 $ 144,524 $ 102,064,218 (78,561,568) 23,647,174
Balance, shares at Dec. 31, 2021 72,992   37,673,110      
Net loss           (7,758,077)
Balance at Jun. 30, 2022 $ 144,524 $ 102,293,464 (86,319,645) 16,118,343
Balance, shares at Jun. 30, 2022 72,992   38,058,245      
Balance at Mar. 31, 2022 $ 144,524 $ 102,161,218 (82,683,602) 19,622,140
Balance, shares at Mar. 31, 2022 72,992   38,058,245      
Stock-based compensation – stock options   $ 132,246 132,246
Net loss (3,636,043) (3,636,043)
Balance at Jun. 30, 2022 $ 144,524 $ 102,293,464 $ (86,319,645) $ 16,118,343
Balance, shares at Jun. 30, 2022 72,992   38,058,245